{"version":"1.0","type":"rich","width":"560px","height":"140px","title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed\/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial","url":"https:\/\/www.myelomasociety.org\/belantamab-mafodotin-bortezomib-and-dexamethasone-vs-daratumumab-bortezomib-and-dexamethasone-in-relapsed-refractory-multiple-myeloma-overall-survival-analysis-and-updated-efficacy-outcomes-of-th\/","author_name":"IMSound","author_url":"https:\/\/www.myelomasociety.org","thumbnail_url":"https:\/\/www.myelomasociety.org\/wp-content\/uploads\/2024\/07\/IMSound-Logo-only-v2.png","html":"<iframe width=\"560px\" height=\"140px\" src=\"https:\/\/www.myelomasociety.org\/belantamab-mafodotin-bortezomib-and-dexamethasone-vs-daratumumab-bortezomib-and-dexamethasone-in-relapsed-refractory-multiple-myeloma-overall-survival-analysis-and-updated-efficacy-outcomes-of-th\/?standalonePlayer\"><\/iframe>"}